Literature DB >> 17431000

Impact of aspirin with or without clopidogrel on postoperative bleeding and blood transfusion in coronary surgical patients treated prophylactically with a low-dose of aprotinin.

Alexandre Ouattara1, Hassine Bouzguenda, Yannick Le Manach, Philippe Léger, Anne Mercadier, Pascal Leprince, Nicolas Bonnet, Gilles Montalescot, Bruno Riou, Pierre Coriat.   

Abstract

AIMS: Aspirin combined with clopidogrel is the treatment of choice for acute coronary syndromes. Although the maintenance of aspirin until surgery does not affect postoperative bleeding after coronary artery bypass graft (CABG) surgery, the latter may be dramatically increased when clopidogrel is continued over a period of 5 days preoperatively. METHODS AND
RESULTS: This prospective observational study included 217 consecutive patients scheduled for first-time CABG. Postoperative bleeding and blood transfusion requirements were compared (equivalence) between patients pretreated during a period of 5 days prior surgery by either aspirin alone (n = 157) or combined with clopidogrel (n = 60). Aprotinin was systematically used in all these patients considered as high risk for bleeding. We found no significant difference between both groups concerning the preoperative characteristics except for unstable angina (33 vs. 19%, P = 0.02) and left main coronary artery stenosis (27 vs. 13%, P = 0.02), which were more frequent in patients receiving clopidogrel. The median chest tube output was similar in both groups 24 h postoperatively at 350 mL (95% CI 150-850) vs. 375 mL (95% CI 175-875), and the difference between groups (7%, 95% CI -9 to 22) did not encompass the predetermined margins of equivalence (25%). No significant difference was found on blood transfusion use (38 vs. 38%, P = 0.99). After adjustment by a propensity score, we found that clopidogrel was not associated with an increased risk of excessive bleeding.
CONCLUSION: In patients undergoing first-time CABG and treated prophylactically with aprotinin, aspirin and clopidogrel may be continued until surgery without increasing postoperative bleeding or transfusion requirements.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17431000     DOI: 10.1093/eurheartj/ehm049

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  6 in total

Review 1.  A review of antiplatelet drugs, coronary artery diseases and cardiopulmonary bypass.

Authors:  Yajun Ren; Kirti Patel; Terry Crane
Journal:  J Extra Corpor Technol       Date:  2010-06

2.  Impact of clopidogrel on bleeding complications and survival in off-pump coronary artery bypass grafting.

Authors:  Hartmuth B Bittner; Sven Lehmann; Ardawan Rastan; Friedrich W Mohr
Journal:  Interact Cardiovasc Thorac Surg       Date:  2011-12-22

3.  STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management.

Authors:  Pierre Tibi; R Scott McClure; Jiapeng Huang; Robert A Baker; David Fitzgerald; C David Mazer; Marc Stone; Danny Chu; Alfred H Stammers; Tim Dickinson; Linda Shore-Lesserson; Victor Ferraris; Scott Firestone; Kalie Kissoon; Susan Moffatt-Bruce
Journal:  J Extra Corpor Technol       Date:  2021-06

4.  Impact of aspirin and clopidogrel interruption on platelet function in patients undergoing major vascular surgery.

Authors:  Yannick Le Manach; David Kahn; Christilla Bachelot-Loza; Frederic Le Sache; David M Smadja; Veronique Remones; Marie-Anne Loriot; Pierre Coriat; Pascale Gaussem
Journal:  PLoS One       Date:  2014-08-20       Impact factor: 3.240

Review 5.  Dual Antiplatelet Therapy before Coronary Artery Bypass Grafting; a Systematic Review and Meta-Analysis.

Authors:  Roxana Sadeghi; Asrin Babahajian; Arash Sarveazad; Naser Kachoueian; Mansour Bahardoust
Journal:  Arch Acad Emerg Med       Date:  2020-05-31

6.  Dual antiplatelet therapy up to the time of non-elective coronary artery bypass grafting with prophylactic platelet transfusion: is it safe?

Authors:  Fida Charif; Righab Hamdan; Genane Youness; Ali El Zein; Mohamad Issa; Yehya Jassar; Mahmoud Younes; Mohamad Saab
Journal:  J Cardiothorac Surg       Date:  2019-11-27       Impact factor: 1.637

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.